Structure-bioactivity relationships of methylxanthines: Trying to make sense of all the promises and the drawbacks

Molecules

Volumn 21, Issue 8, 2016, Pages

  Monteiro, João P ^a   Alves, Marco G ^b   Oliveira, Pedro F ^a   Silva, Branca M ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Caffeine; Cancer; Diabetes; Methylxanthine; Neurodegenerative diseases; Structure activity relationship; Theobromine; Theophylline

Indexed keywords

CAFFEINE; METHYLXANTHINE; PLANT MEDICINAL PRODUCT; THEOBROMINE; THEOPHYLLINE; XANTHINE DERIVATIVE;

ANIMAL; CACAO; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; SECONDARY METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CACAO; CAFFEINE; HUMANS; MOLECULAR STRUCTURE; PHYTOCHEMICALS; SECONDARY METABOLISM; STRUCTURE-ACTIVITY RELATIONSHIP; THEOBROMINE; THEOPHYLLINE; XANTHINES;

EID: 84982747125     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21080974     Document Type: Review

References (377)

1. Stasolla, C.; Katahira, R.; Thorpe, T. A.; Ashihara, H. Purine and pyrimidine nucleotide metabolism in higher plants. J. Plant Physiol. 2003, 160, 1271-1295.
2. Zrenner, R.; Stitt, M.; Sonnewald, U.; Boldt, R. Pyrimidine and purine biosynthesis and degradation in plants. Annu. Rev. Plant Biol. 2006, 57, 805-836.
3. Glantzounis, G. K.; Tsimoyiannis, E. C.; Kappas, A. M.; Galaris, D. A. Uric Acid and Oxidative Stress. Curr. Pharm. Des. 2005, 11, 4145-4151.
4. Hollingsworth, R. G.; Armstrong, J. W.; Campbell, E. Pest Control: Caffeine as a repellent for slugs and snails. Nature 2002, 417, 915-916.
5. Frischknecht, P. M.; Ulmer-Dufek, J.; Baumann, T. W. Purine alkaloid formation in buds and developing leaflets of Coffea arabica: Expression of an optimal defence strategy? Phytochemistry 1986, 25, 613-616.
6. Wolf, A.; Bray, G. A.; Popkin, B. M. A short history of beverages and how our body treats them. Obes. Rev. 2008, 9, 151-164.
7. Sotelo, A.; Soleri, D.; Wacher, C.; Sánchez-Chinchillas, A.; Argote, R. M. Chemical and nutritional composition of Tejate, a traditional maize and cacao beverage from the central valleys of Oaxaca, Mexico. Plant Foods Hum. Nutr. 2012, 67, 148-155.
8. Stavric, B. Methylxanthines: Toxicity to humans. 1. Theophylline. Food Chem. Toxicol. 1988, 26, 541-565.
9. Ashihara, H.; Sano, H.; Crozier, A. Caffeine and related purine alkaloids: Biosynthesis, catabolism, function and genetic engineering. Phytochemistry 2008, 69, 841-856.
10. Nehlig, A.; Daval, J.-L.; Debry, G. Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 1992, 17, 139-170.
11. Fredholm, B. B.; Bättig, K.; Holmén, J.; Nehlig, A.; Zvartau, E. E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51, 83-133.
12. Jacobson, B. H.; Weber, M. D.; Claypool, L.; Hunt, L. E. Effect of caffeine on maximal strength and power in élite male athletes. Br. J. Sports Med. 1992, 26, 276-280.
13. Anselme, F.; Collomp, K.; Mercier, B.; Ahmaïdi, S.; Prefaut, C. Caffeine increases maximal anaerobic power and blood lactate concentration. Eur. J. Appl. Physiol. Occup. Physiol. 1992, 65, 188-191.
14. Jackman, M.; Wendling, P.; Friars, D.; Graham, T. E. Metabolic, catecholamine, and endurance responses to caffeine during intense exercise. J. Appl. Physiol. 1996, 81, 1658-1663.
15. Graham, T. E.; Spriet, L. L. Performance and metabolic responses to a high caffeine dose during prolonged exercise. J. Appl. Physiol. 1991, 71, 2292-2298.
16. Kovacs, E. M. R.; Stegen, J. H. C. H.; Brouns, F. Effect of caffeinated drinks on substrate metabolism, caffeine excretion, and performance. J. Appl. Physiol. 1998, 85, 709-715.
17. Greer, F.; Friars, D.; Graham, T. E. Comparison of caffeine and theophylline ingestion: Exercise metabolism and endurance. J. Appl. Physiol. 2000, 89, 1837-1844.
18. Chapman, R. F.; Mickleborough, T. D. The effects of caffeine on ventilation and pulmonary function during exercise: An often-overlooked response. Phys. Sportsmed. 2009, 37, 97-103.
19. Barnes, P. J. Theophylline. Am. J. Respir. Crit. Care Med. 2013, 188, 901-906.
20. Bell, M.; Jackson, E.; Mi, Z.; McCombs, J.; Carcillo, J. Low-dose theophylline increases urine output in diuretic-dependent critically ill children. Intensive Care Med. 1998, 24, 1099-1105.
21. Salihović, M.; Huseinović, S.; Špirtović-Halilović, S.; Osmanović, A.; Dedić, A.; Ašimović, Z.; Završnik, D. DFT study and biological activity of some methylxanthines. Bull. Chem. Technol. Bosnia Herzeg. 2014, 42, 31-36.
22. Talik, P.; Krzek, J.; Ekiert, R. J. Analytical techniques used for determination of methylxanthines and their analogues-Recent advances. Sep. Purif. Rev. 2012, 41, 1-61.
23. McCall, A. L.; Millington, W. R.; Wurtman, R. J. Blood-brain barrier transport of caffeine: Dose-related restriction of adenine transport. Life Sci. 1982, 31, 2709-2715.
24. Beale, J. M., Jr. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 12th ed.; LippincottWilliams & Wilkins, Wolters Kuwer: Philadelphia, PA, USA, 2011.
25. Pavia, D. L. Coffee, Tea, or Cocoa. A trio of experiments including the isolation of theobromine from cocoa. J. Chem. Educ. 1973, 50, 791.
26. Gardenhire, D. S. Rau's Respiratory Care Pharmacology, 9th ed.; Elsevier Health Sciences: St. Louis, MO, USA, 2016; p. 140.
27. Ashihara, H.; Suzuki, T. Distribution and biosynthesis of caffeine in plants. Front. Biosci. 2004, 9, 1864-1876.
28. Ashihara, H.; Crozier, A. Biosynthesis and metabolism of caffeine and related purine alkaloids in plants. In Advances in Botanical Research; Callow, J. A., Ed.; Academic Press: New York, NY, USA, 1999; Volume 30, pp. 117-205.
29. Mazzafera, P.; Carvalho, A. Breeding for low seed caffeine content of coffee (Coffea L.) by interspecific hybridization. Euphytica 1991, 59, 55-60.
30. Lin, Y.-S.; Tsai, Y.-J.; Tsay, J.-S.; Lin, J.-K. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J. Agric. Food Chem. 2003, 51, 1864-1873.
31. Fernandez, P. L.; Martin, M. J.; Gonzalez, A. G.; Pablos, F. HPLC determination of catechins and caffeine in tea. Differentiation of green, black and instant teas. Analyst 2000, 125, 421-425.
32. Stavric, B. Methylxanthines: Toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines. Food Chem. Toxicol. 1988, 26, 725-733.
33. Baumann, T. W.; Schulthess, B. H.; Hänni, K. Guaraná (Paullinia cupana) rewards seed dispersers without intoxicating them by caffeine. Phytochemistry 1995, 39, 1063-1070.
34. Weckerle, C. S.; Stutz, M. A.; Baumann, T. W. Purine alkaloids in Paullinia. Phytochemistry 2003, 64, 735-742.
35. Kretschmar, J. A.; Baumann, T. W. Caffeine in Citrus flowers. Phytochemistry 1999, 52, 19-23.
36. Atawodi, S. E.-O.; Pfundstein, B.; Haubner, R.; Spiegelhalder, B.; Bartsch, H.; Owen, R. W. Content of polyphenolic compounds in the nigerian stimulants Cola nitida ssp. alba, Cola nitida ssp. rubra A. Chev, and Cola acuminata Schott & Endl and their antioxidant capacity. J. Agric. Food Chem. 2007, 55, 9824-9828.
37. Frary, C. D.; Johnson, R. K.; Wang, M. Q. Food sources and intakes of caffeine in the diets of persons in the United States. J. Am. Diet. Assoc. 2005, 105, 110-113.
38. Gilbert, R. M.; Marshman, J. A.; Schwieder, M.; Berg, R. Caffeine content of beverages as consumed. Can. Med. Assoc. J. 1976, 114, 205-208.
39. Moderno, P. M.; Carvalho, M.; Silva, B. M. Recent patents on Camellia sinensis: Source of health promoting compounds. Recent Pat. Food Nutr. Agric. 2009, 1, 182-192.
40. Seeram, N. P.; Henning, S. M.; Niu, Y.; Lee, R.; Scheuller, H. S.; Heber, D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J. Agric. Food Chem. 2006, 54, 1599-1603.
41. Carvalho, M.; Jerónimo, C.; Valentão, P.; Andrade, P. B.; Silva, B. M. Green tea: A promising anticancer agent for renal cell carcinoma. Food Chem. 2010, 122, 49-54.
42. Dias, T. R.; Tomás, G.; Teixeira, N. F.; Alves, M. G.; Oliveira, P. F.; Silva, B. M. White tea (Camellia sinensis L.): Antioxidant properties and beneficial health effects. Int. J. Food Sci. Nutr. Diet. 2013, 11, 1-15.
43. Martins, A. D.; Alves, M. G.; Bernardino, R. L.; Dias, T. R.; Silva, B. M.; Oliveira, P. F. Effect of white tea (Camellia sinensis (L.)) extract in the glycolytic profile of Sertoli cell. Eur. J. Nutr. 2013, 53, 1383-1391.
44. Unachukwu, U. J.; Ahmed, S.; Kavalier, A.; Lyles, J. T.; Kennelly, E. J. White and green teas (Camellia sinensis var. sinensis): Variation in phenolic, methylxanthine, and antioxidant profiles. J. Food Sci. 2010, 75, C541-C548.
45. Boros, K.; Jedlinszki, N.; Csupor, D. Theanine and caffeine content of infusions prepared from commercial tea samples. Pharmacogn. Mag. 2016, 12, 75-79.
46. Crozier, T. W. M.; Stalmach, A.; Lean, M. E. J.; Crozier, A. Espresso coffees, caffeine and chlorogenic acid intake: Potential health implications. Food Funct. 2012, 3, 30-33.
47. McCusker, R. R.; Fuehrlein, B.; Goldberger, B. A.; Gold, M. S.; Cone, E. J. Caffeine content of decaffeinated coffee. J. Anal. Toxicol. 2006, 30, 611-613.
48. Astill, C.; Birch, M. R.; Dacombe, C.; Humphrey, P. G.; Martin, P. T. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. J. Agric. Food Chem. 2001, 49, 5340-5347.
49. Blauch, J. L.; Tarka, S. M. HPLC determination of caffeine and theobromine in coffee, tea, and instant hot cocoa Mixes. J. Food Sci. 1983, 48, 745-747.
50. Bispo, M. S.; Veloso, M. C. C.; Pinheiro, H. L. C.; de Oliveira, R. F. S.; Reis, J. O. N.; de Andrade, J. B. Simultaneous determination of caffeine, theobromine, and theophylline by high-performance liquid chromatography. J. Chromatogr. Sci. 2002, 40, 45-48.
51. Hicks, M. B.; Hsieh, Y. H. P.; Bell, L. N. Tea preparation and its influence on methylxanthine concentration. Food Res. Int. 1996, 29, 325-330.
52. Alañón, M. E.; Castle, S. M.; Siswanto, P. J.; Cifuentes-Gómez, T.; Spencer, J. P. E. Assessment of flavanol stereoisomers and caffeine and theobromine content in commercial chocolates. Food Chem. 2016, 208, 177-184.
53. Cooper, K. A.; Campos-Giménez, E.; Jiménez Alvarez, D.; Rytz, A.; Nagy, K.; Williamson, G. Predictive relationship between polyphenol and nonfat cocoa solids content of chocolate. J. Agric. Food Chem. 2008, 56, 260-265.
54. Tokusoglu, Ö.; Ünal, K. M. Optimized method for simultaneous determination of catechin, gallic acid, and methylxanthine compounds in chocolate using RP-HPLC. Eur. Food Res. Technol. 2002, 215, 340-346.
55. Ashihara, H.; Kato, M.; Crozier, A. Distribution, biosynthesis and catabolism of methylxanthines in plants. In Methylxanthines; Springer Berlin Heidelberg: Berlin, Germany; Heidelberg, Germany, 2011; pp. 11-31.
56. Misako, K.; Kouichi, M. Caffeine synthase and related methyltransferases in plants. Front. Biosci. 2004, 9, 1833-1842.
57. Koshiishi, C.; Kato, A.; Yama, S.; Crozier, A.; Ashihara, H. A new caffeine biosynthetic pathway in tea leaves: Utilisation of adenosine released from the S-adenosyl-L-methionine cycle. FEBS Lett. 2001, 499, 50-54.
58. Zajac, M. A.; Zarkzewski, A. G.; Kowal, M. G.; Narayan, S. A Novel Method of Caffeine Synthesis from Uracil; Taylor & Francis: Philadelphia, PA, USA, 2003; Volume 33, p. 7.
59. Kumar, N. S.; Chandran, T. B.; Namratha, S.; Bharat, B. R.; Kumar, C. H. P.; Kishore, V. Production of theobromine from Pseudomonas sp. Int. Res. J. Pharm. 2013, 4.
60. Nanjundaiah, S.; Bhatt, P.; Rastogi, N. K.; Thakur, M. S. Response surface optimization for decaffeination and theophylline production by Fusarium solani. Appl. Biochem. Biotechnol. 2015, 178, 58-75.
61. Begas, E.; Kouvaras, E.; Tsakalof, A.; Papakosta, S.; Asprodini, E. K. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr. 2007, 21, 190-200.
62. El-Yazigi, A.; Shabib, S.; Al-Rawithi, S.; Yusuf, A.; Legayada, E. S.; Al-Humidan, A. Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases. J. Clin. Pharmacol. 1999, 39, 366-372.
63. Krul, C.; Hageman, G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998, 709, 27-34.
64. Bendriss, E.-K.; Markoglou, N.; Wainer, I. W. Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J. Chromatogr. B Biomed. Sci. Appl. 2000, 746, 331-338.
65. Van Soeren, M.; Mohr, T.; Kjaer, M.; Graham, T. E. Acute effects of caffeine ingestion at rest in humans with impaired epinephrine responses. J. Appl. Physiol. 1996, 80, 999-1005.
66. Newton, R.; Broughton, L. J.; Lind, M. J.; Morrison, P. J.; Rogers, H. J.; Bradbrook, I. D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol. 1981, 21, 45-52.
67. Georga, K. A.; Samanidou, V. F.; Papadoyannis, I. N. IImproved micro-method for the HPLC analysis of caffeine and its demethylated metabolites in human biological fluids after SPE. J. Liq. Chromatogr. Relat. Technol. 2000, 23, 1523-1537.
68. Fenske, M. Caffeine determination in human saliva and urine by TLC and ultraviolet absorption densitometry. Chromatographia 2006, 65, 233-238.
69. Emara, S. Simultaneous determination of caffeine, theophylline and theobromine in human plasma by on-line solid-phase extraction coupled to reversed-phase chromatography. Biomed. Chromatogr. 2004, 18, 479-485.
70. Setchell, K. D. R.; BethWelsh, M.; Klooster, M. J.; Balistreri, W. F.; Lim, C. K. Rapid high-performance liquid chromatography assay for salivary and serum caffeine following an oral load. J. Chromatogr. A 1987, 385, 267-274.
71. Srdjenovic, B.; Djordjevic-Milic, V.; Grujic, N.; Injac, R.; Lepojevic, Z. Simultaneous HPLC determination of caffeine, theobromine, and theophylline in food, drinks, and herbal products. J. Chromatogr. Sci. 2008, 46, 144-149.
72. González-Nuñez, L. N.; Cañizares-Macías, M. P. Focused microwaves-assisted extraction of theobromine and caffeine from cacao. Food Chem. 2011, 129, 1819-1824.
73. Saldaña, M. D. A.; Zetzl, C.; Mohamed, R. S.; Brunner, G. Extraction of Methylxanthines from Guaraná Seeds, Maté Leaves, and Cocoa Beans Using Supercritical Carbon Dioxide and Ethanol. J. Agric. Food Chem. 2002, 50, 4820-4826.
74. Caudle, A. G.; Gu, Y.; Bell, L. N. Improved analysis of theobromine and caffeine in chocolate food products formulated with cocoa powder. Food Res. Int. 2001, 34, 599-603.
75. Hulbert, G. J.; Biswal, R. N.; Mehr, C. B.; Walker, T. H.; Collins, J. L. Solid/liquid extraction of caffeine from guaraná with methylene chloride/Extracción solido-liquido de cafeina de guarana con cloruro de metileno. Food Sci. Technol. Int. 1998, 4, 53-58.
76. Belžčak, A.; Komes, D.; Horžić, D.; Ganić, K. K.; Karlović, D. Comparative study of commercially available cocoa products in terms of their bioactive composition. Food Res. Int. 2009, 42, 707-716.
77. Xia, Z.; Ni, Y.; Kokot, S. Simultaneous determination of caffeine, theophylline and theobromine in food samples by a kinetic spectrophotometric method. Food Chem. 2013, 141, 4087-4093.
78. De Aragão, N. M.; Veloso, M. C. C.; Bispo, M. S.; Ferreira, S. L. C.; de Andrade, J. B. Multivariate optimisation of the experimental conditions for determination of three methylxanthines by reversed-phase high-performance liquid chromatography. Talanta 2005, 67, 1007-1013.
79. Zacharis, C. K.; Kika, F. S.; Tzanavaras, P. D.; Fytianos, K. Development and validation of a rapid ultra high pressure liquid chromatographic method for the determination of methylxanthines in herbal infusions. J. Chromatogr. B 2013, 927, 218-222.
80. Hasegawa, T.; Takahashi, K.; Saijo, M.; Ishii, T.; Nagata, T. Rapid determination of theophylline, theobromine and caffeine in dietary supplements containing guarana by ultra-performance liquid chromatography. Shokuhin Eiseigaku Zasshi 2009, 50, 304-310.
81. Kumazawa, T.; Seno, H.; Lee, X.-P.; Ishii, A.; Watanabe-Suzuki, K.; Sato, K.; Suzuki, O. Extraction of methylxanthines from human body fluids by solid-phase microextraction. Anal. Chim. Acta 1999, 387, 53-60.
82. Shrivas, K.; Wu, H.-F. Rapid determination of caffeine in one drop of beverages and foods using drop-to-drop solvent microextraction with gas chromatography/mass spectrometry. J. Chromatogr. A 2007, 1170, 9-14.
83. Tserng, K. Y. Gas chromatographic-mass spectrometric quantitation of theophylline and its metabolites in biological fluids. J. Pharm. Sci. 1983, 72, 526-529.
84. Khanchi, A. R.; Mahani, M. K.; Hajihosseini, M.; Maragheh, M. G.; Chaloosi, M.; Bani, F. Simultaneous spectrophotometric determination of caffeine and theobromine in Iranian tea by artificial neural networks and its comparison with PLS. Food Chem. 2007, 103, 1062-1068.
85. Khoshayand, M. R.; Abdollahi, H.; Shariatpanahi, M.; Saadatfard, A.; Mohammadi, A. Simultaneous spectrophotometric determination of paracetamol, ibuprofen and caffeine in pharmaceuticals by chemometric methods. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2008, 70, 491-499.
86. Singh, D. K.; Sahu, A. Spectrophotometric determination of caffeine and theophylline in pure alkaloids and its application in pharmaceutical formulations. Anal. Biochem. 2006, 349, 176-180.
87. Armenta, S.; Garrigues, S.; de la Guardia, M. Solid-phase FT-Raman determination of caffeine in energy drinks. Anal. Chim. Acta 2005, 547, 197-203.
88. Moreira, A. B.; Dias, I. L. T.; Neto, G. O.; Zagatto, E. A. G.; Ferreira, M. M. C.; Kubota, L. T. Solid-phase spectrofluorimetric determination of acetylsalicylic acid and caffeine in pharmaceutical preparations using partial least-squares multivariate calibration. Talanta 2005, 67, 65-69.
89. Alves, J. C. L.; Poppi, R. J. Simultaneous determination of acetylsalicylic acid, paracetamol and caffeine using solid-phase molecular fluorescence and parallel factor analysis. Anal. Chim. Acta 2009, 642, 212-216.
90. Paradkar, M. M.; Irudayaraj, J. Rapid determination of caffeine content in soft drinks using FTIR-ATR spectroscopy. Food Chem. 2002, 78, 261-266.
91. Meinhart, A. D.; Bizzotto, C. S.; Ballus, C. A.; Prado, M. A.; Bruns, R. E.; Filho, J. T.; Godoy, H. T. Optimisation of a CE method for caffeine analysis in decaffeinated coffee. Food Chem. 2010, 120, 1155-1161.
92. Dilek Uysal, U.; Aturki, Z.; Raggi, M. A.; Fanali, S. Separation of catechins and methylxanthines in tea samples by capillary electrochromatography. J. Sep. Sci. 2009, 32, 1002-1010.
93. Horie, H.; Mukai, T.; Kohata, K. Simultaneous determination of qualitatively important components in green tea infusions using capillary electrophoresis. J. Chromatogr. A 1997, 758, 332-335.
94. Thormann, W.; Minger, A.; Molteni, S.; Caslavska, J.; Gebauer, P. Determination of substituted purines in body fluids by micellar electrokinetic capillary chromatography with direct sample injection. J. Chromatogr. 1992, 593, 275-288.
95. Zhao, Y.; Lunte, C. E. Determination of caffeine and its metabolites by micellar electrokinetic capillary electrophoresis. J. Chromatogr. B Biomed. Sci. Appl. 1997, 688, 265-274.
96. Bonoli, M.; Colabufalo, P.; Pelillo, M.; Gallina Toschi, T.; Lercker, G. Fast determination of catechins and xanthines in tea beverages by micellar electrokinetic chromatography. J. Agric. Food Chem. 2003, 51, 1141-1147.
97. Sanghavi, B. J.; Srivastava, A. K. Simultaneous voltammetric determination of acetaminophen, aspirin and caffeine using an in situ surfactant-modified multiwalled carbon nanotube paste electrode. Electrochim. Acta 2010, 55, 8638-8648.
98. Yang, S.; Yang, R.; Li, G.; Qu, L.; Li, J.; Yu, L. Nafion/multi-wall carbon nanotubes composite film coated glassy carbon electrode for sensitive determination of caffeine. J. Electroanal. Chem. 2010, 639, 77-82.
99. Cook, C. E.; Tallent, C. R.; Amerson, E. W.; Myers, M. W.; Kepler, J. A.; Taylor, G. F.; Christensen, H. D. Caffeine in plasma and saliva by a radioimmunoassay procedure. J. Pharmacol. Exp. Ther. 1976, 199, 679-686.
100. Van Aerde, P.; Moerman, E.; Van Severen, R.; Braeckman, P. Determination of plasma theophylline by straight-phase high-performance liquid chromatography: Elimination of interfering caffeine metabolites. J. Chromatogr. 1981, 222, 467-474.
101. Aranda, M.; Morlock, G. Simultaneous determination of caffeine, ergotamine, and metamizol in solid pharmaceutical formulation by HPTLC-UV-FLD with mass confirmation by online HPTLC-ESI-MS. J. Chromatogr. Sci. 2007, 45, 251-255.
102. Ford, M. J.; Deibel, M. A.; Tomkins, B. A.; van Berkel, G. J. Quantitative thin-layer chromatography/mass spectrometry analysis of caffeine using a surface sampling probe electrospray ionization tandem mass spectrometry system. Anal. Chem. 2005, 77, 4385-4389.
103. Khasanov, V. V.; Dychko, K. A.; Kuryaeva, T. T.; Ryzhova, G. L.; Mal'tseva, E. V. A new procedure for caffeine determination. Russ. J. Appl. Chem. 2005, 78, 1427-1429.
104. Llorent-Martínez, E. J.; García-Reyes, J. F.; Ortega-Barrales, P.; Molina-Díaz, A. Solid-phase ultraviolet sensing system for determination of methylxanthines. Anal. Bioanal. Chem. 2005, 382, 158-163.
105. Adams, R. F.; Vandemark, F. L.; Schmidt, G. J. More sensitive high-pressure liquid-chromatographic determiantion of theophylline in serum. Clin. Chem. 1976, 22, 1903-1906.
106. Meyer, A.; Ngiruwonsanga, T.; Henze, G. Determination of adenine, caffeine, theophylline and theobromine by HPLC with amperometric detection. Anal. Bioanal. Chem. 1996, 356, 284-287.
107. Zhu, X.; Chen, B.; Ma, M.; Luo, X.; Zhang, F.; Yao, S.; Wan, Z.; Yang, D.; Hang, H. Simultaneous analysis of theanine, chlorogenic acid, purine alkaloids and catechins in tea samples with the help of multi-dimension information of on-line high performance liquid chromatography/electrospray-mass spectrometry. J. Pharm. Biomed. Anal. 2004, 34, 695-704.
108. Marchei, E.; Pellegrini, M.; Pacifici, R.; Palmi, I.; Pichini, S. Development and validation of a high-performance liquid chromatography-mass spectrometry assay for methylxanthines and taurine in dietary supplements. J. Pharm. Biomed. Anal. 2005, 37, 499-507.
109. Ptolemy, A. S.; Tzioumis, E.; Thomke, A.; Rifai, S.; Kellogg, M. Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: A single analytical protocol applicable to cocoa intervention studies. J. Chromatogr. B 2010, 878, 409-416.
110. Huck, C. W.; Guggenbichler, W.; Bonn, G. K. Analysis of caffeine, theobromine and theophylline in coffee by near infrared spectroscopy (NIRS) compared to high-performance liquid chromatography (HPLC) coupled to mass spectrometry. Anal. Chim. Acta 2005, 538, 195-203.
111. Bech, B. H.; Bossi, R. Simultaneous determination of methylxanthines and cotinine in human plasma by solid-phase extraction followed by LC-MS-MS. Spectroscopy 2015, 27, 31-34.
112. Rail, T. W. Central nervous system stimulants, the xanthines. In In The Pharmacologic Basis of Therapeutics, 6th ed.; Gilman, L. G. A., Ed.; Macmillan: Toronto, ON, Canada, 1980; p. 592.
113. Moffat, A. Clarke's 'Isolation and Identification of Drugs' (2nd edition) Senior consulting editor: A. C. Moffat Reviewed by I A Blair. J. Pharm. Pharmacol. 1986, 38, 942-944.
114. Tarka, S. M.; Cornish, H. H. The toxicology of cocoa and methylxanthines: A review of the literature. CRC Crit. Rev. Toxicol. 1982, 9, 275-312.
115. Testa, B. Purine receptors and heir pharmacological roles. In Advances in Drug Research; Jovanovic, H. B., Ed.; Academic Press: London, UK, 1989; Volume 18, pp. 292-430.
116. Mueller, C. E.; Shi, D.; Manning, M.; Daly, J. W. Synthesis of paraxanthine analogs (1, 7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: Structure-activity relationships at adenosine receptors. J. Med. Chem. 1993, 36, 3341-3349.
117. Miyamoto, K.-I.; Sakai, R.; Yamamoto, Y.; Konno, K.; Sanae, F.; Hasegawa, T.; Takagi, K. Selective Bronchodilators from 1-(51-Oxohexyl) xanthines. J. Pharm. Pharmacol. 1992, 44, 888-892.
118. Takagi, K.; Hasegawa, T.; Kuzuya, T.; Ogawa, K.; Watanabe, T.; Satake, T.; Miyamoto, K.; Wakusawa, S.; Koshiura, R. Structure-activity relationship in N3-alkyl-xanthine derivatives. Jpn. J. Pharmacol. 1988, 46, 373-378.
119. Ali, H.; Müller, C. E.; Daly, J. W.; Beaven, M. A. Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: Evidence for inhibition of antigen binding to IgE. J. Pharmacol. Exp. Ther. 1991, 258, 954-962.
120. Bruns, R. F. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. 1981, 30, 325-333.
121. Bruns, R. F.; Daly, J. W.; Snyder, S. H. Adenosine receptor binding: Structure-activity analysis generates extremely potent xanthine antagonists. Proc. Natl. Acad. Sci. USA 1983, 80, 2077-2080.
122. 2-adenosine receptors. J. Med. Chem. 1985, 28, 487-492.
123. León-Carmona, J. R.; Galano, A. Is caffeine a good scavenger of oxygenated free radicals? J. Phys. Chem. B 2011, 115, 4538-4546.
124. Grucka-Mamczar, E.; Zalejska-Fiolka, J.; Chlubek, D.; Kasperczyk, S.; Blaszczyk, U.; Kasperczyk, A.; Swietochowska, E.; Birkner, E. The influence of sodium fluoride and caffeine on the activity of antioxidative enzymes and the concentration of malondialdehyde in rat liver. Fluoride 2009, 42, 105-109.
125. Ofluoglu, E.; Pasaoglu, H.; Pasaoglu, A. The effects of caffeine on L-arginine metabolism in the brain of rats. Neurochem. Res. 2008, 34, 395-399.
126. Azam, S.; Hadi, N.; Khan, N. U.; Hadi, S. M. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2003, 9, BR325-BR330.
127. Choi, O. H.; Shamim, M. T.; Padgett, W. L.; Daly, J. W. Caffeine and theophylline analogues: Correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci. 1988, 43, 387-398.
128. McPherson, P. S.; Kim, Y.-K.; Valdivia, H.; Knudson, C. M.; Takekura, H.; Franzini-Armstrong, C.; Coronadot, R.; Campbell, K. P. The brain ryanodine receptor: A caffeine-sensitive calcium release channel. Neuron 1991, 7, 17-25.
129. Chen, J.-F.; Chern, Y. Impacts of methylxanthines and adenosine receptors on neurodegeneration: Human and experimental studies. In Methylxanthines; Springer: Berlin/Heidelberg, Germany, 2011; pp. 267-310.
130. Tazzeo, T.; Bates, G.; Roman, H. N.; Lauzon, A.-M.; Khasnis, M. D.; Eto, M.; Janssen, L. J. Caffeine relaxes smooth muscle through actin depolymerization. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303, L334-L342.
131. Dent, G.; Giembycz, M. A.; Rabe, K. F.; Wolf, B.; Barnes, P. J.; Magnussen, H. Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am. J. Respir. Cell Mol. Biol. 1994, 10, 565-572.
132. 2+ release channel. Pharmacology 1997, 54, 135-143.
133. Nawrot, P.; Jordan, S.; Eastwood, J.; Rotstein, J.; Hugenholtz, A.; Feeley, M. Effects of caffeine on human health. Food Addit. Contam. 2003, 20, 1-30.
134. Fredholm, B. B.; Jzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
135. Olah, M. E.; Stiles, G. L. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 581-606.
136. Green, R. D.; Stanberry, L. R. Elevation of cyclic amp in C-1300 murine neuroblastoma by adenosine and related compounds and the antagonism of this response by methylxanthines. Biochem. Pharmacol. 1977, 26, 37-43.
137. Boulenger, J. P.; Patel, J.; Marangos, P. J. Effects of caffeine and theophylline on adenosine and benzodiazepine receptors in human brain. Neurosci. Lett. 1982, 30, 161-166.
138. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 2001, 61, 443-448.
139. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, J. M. Comparative pharmacology of human adenosine receptor subtypes-Characterization of stably transfected receptors in CHO cells. Naunyn Schmiedeberg's Arch. Pharmacol. 1997, 357, 1-9.
140. Daly, J. W.; Butts-Lamb, P.; Padgett, W. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. 1983, 3, 69-80.
141. 3 adenosine receptor ligands: History and perspectives. Med. Res. Rev. 2000, 20, 103-128.
142. Fredholm, B. B.; Persson, C. G. A. Xanthine derivatives as adenosine receptor antagonists. Eur. J. Pharmacol. 1982, 81, 673-676.
143. Franco, R.; Oñatibia-Astibia, A.; Martínez-Pinilla, E. Health benefits of methylxanthines in cacao and chocolate. Nutrients 2013, 5, 4159-4173.
144. Shi, D.; Daly, J. W. Chronic effects of xanthines on levels of central receptors in mice. Cell. Mol. Neurobiol. 1999, 19, 719-732.
145. Carney, J. M.; Holloway, F. A.; Modrow, H. E. Discriminative stimulus properties of methylxanthines and their metabolites in rats. Life Sci. 1985, 36, 913-920.
146. 2 adenosine receptors. Naunyn Schmiedeberg Arch. Pharmacol. 1985, 330, 212-221.
147. Moro, S.; Gao, Z.-G.; Jacobson, K. A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. 2006, 26, 131-159.
148. Baraldi, P. G.; Fruttarolo, F.; Tabrizi, M. A.; Romagnoli, R.; Preti, D. Novel 8-heterocyclyl xanthine derivatives in drug development-An update. Expert Opin. Drug Discov. 2007, 2, 1161-1183.
149. 1 receptor. Bioorg. Med. Chem. 2015, 23, 6641-6649.
150. Jacobson, K. A.; von Lubitz, D. K. J. E.; Daly, J. W.; Fredholm, B. B. Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol. Sci. 1996, 17, 108-113.
151. 2A adenosine receptors and their function in human platelets. Circulation 1999, 99, 2499-2502.
152. Biaggioni, I.; Paul, S.; Puckett, A.; Arzubiaga, C. Caffeine and theophylline as adenosine receptor antagonists in humans. J. Pharmacol. Exp. Ther. 1991, 258, 588-593.
153. Herman, A.; Herman, A. P. Caffeine's mechanisms of action and its cosmetic use. Skin Pharmacol. Physiol. 2013, 26, 8-14.
154. Beavo, J. A.; Rogers, N. L.; Crofford, O. B.; Hardman, J. G.; Sutherland, E. W.; Newman, E. V. Effects of xanthine derivatives on lipolysis and on adenosine 31, 51-monophosphate phosphodiesterase activity. Mol. Pharmacol. 1970, 6, 597-603.
155. Sugimoto, N.; Miwa, S.; Hitomi, Y.; Nakamura, H.; Tsuchiya, H.; Yachie, A. Theobromine, the primary methylxanthine found in Theobroma cacao, prevents malignant glioblastoma proliferation by negatively regulating phosphodiesterase-4, extracellular signal-regulated kinase, Akt/mammalian target of rapamycin kinase, and nuclear factor-κB. Nutr. Cancer 2014, 66, 419-423.
156. Ruangkittisakul, A.; Ballanyi, K. Methylxanthine reversal of opioid-evoked inspiratory depression via phosphodiesterase-4 blockade. Respir. Physiol. Neurobiol. 2010, 172, 94-105.
157. Sassone-Corsi, P. The cyclic AMP pathway. Cold Spring Harb. Perspect. Biol. 2012, 4.
158. Francis, S. H.; Sekhar, K. R.; Ke, H.; Corbin, J. D. Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. In Methylxanthines; Springer: Berlin/Heidelberg, Germany, 2011; pp. 93-133.
159. Daly, J. W. Caffeine analogs: Biomedical impact. Cell. Mol. Life Sci. 2007, 64, 2153-2169.
160. Rabe, K.; Magnussen, H.; Dent, G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur. Respir. J. 1995, 8, 637-642.
161. Pissarnitski, D. A.; Asberom, T.; Boyle, C. D.; Chackalamannil, S.; Chintala, M.; Clader, J. W.; Greenlee, W. J.; Hu, Y.; Kurowski, S.; Myers, J.; et al. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction. Bioorg. Med. Chem. Lett. 2004, 14, 1291-1294.
162. Arnold, R.; Beer, D.; Bhalay, G.; Baettig, U.; Collingwood, S. P.; Craig, S.; Devereux, N.; Dunstan, A.; Glen, A.; Gomez, S.; et al. 8-Aryl xanthines potent inhibitors of phosphodiesterase 5. Bioorg. Med. Chem. Lett. 2002, 12, 2587-2590.
163. Huai, Q.; Liu, Y.; Francis, S. H.; Corbin, J. D.; Ke, H. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 2004, 279, 13095-13101.
164. Scapin, G.; Patel, S. B.; Chung, C.; Varnerin, J. P.; Edmondson, S. D.; Mastracchio, A.; Parmee, E. R.; Singh, S. B.; Becker, J. W.; van der Ploeg, L. H. T.; et al. Crystal structure of human phosphodiesterase 3B: Atomic basis for substrate and inhibitor specificity. Biochemistry 2004, 43, 6091-6100.
165. Lopez, F.; Miller, L. G.; Greenblatt, D. J.; Kaplan, G. B.; Shader, R. I. Interaction of caffeine with the GABAA receptor complex: Alterations in receptor function but not ligand binding. Eur. J. Pharmacol. Mol. Pharmacol. 1989, 172, 453-459.
166. Sugimoto, T.; Sugimoto, M.; Uchida, I.; Mashimo, T.; Okada, S. Inhibitory effect of theophylline on recombinant GABAA receptor. Neuro Rep. 2001, 12, 489-493.
167. Shi, D.; Padgett, W. L.; Daly, J. W. Caffeine analogs: Effects on ryanodine-sensitive calcium-release channels and GABAA receptors. Cell. Mol. Neurobiol. 2003, 23, 331-347.
168. Roca, D. J.; Schiller, G. D.; Farb, D. H. Chronic caffeine or theophylline exposure reduces-aminobutyric acid/benzodiazepine receptor site interactions. Mol. Pharmacol. 1988, 33, 481-485.
169. Daly, J. W. Alkylxanthines as research tools. J. Auton. Nerv. Syst. 2000, 81, 44-52.
170. 2+. Biochim. Biophys. Acta BBA Biomembr. 2014, 1838, 867-873.
171. Müller, C. E.; Daly, J. W. Stimulation of calcium release by caffeine analogs in pheochromocytoma cells. Biochem. Pharmacol. 1993, 46, 1825-1829.
172. 2+ release channel of skeletal muscle sarcoplasmic reticulum by caffeine and related compounds. Arch. Biochem. Biophys. 1988, 267, 75-86.
173. 2+ release in cardiomyoblast cells. J. Ethnopharmacol. 2013, 150, 389-392.
174. 2+ release channels in longitudinal muscle of intestine. Am. J. Physiol. Cell Physiol. 1994, 266, C1421-C1431.
175. 2+-release by methylxanthine analogues. J. Med. Chem. 1999, 42, 2527-2534.
176. Fredholm, B. B. On the mechanism of action of theophylline and caffeine. Acta Medica Scand. 1985, 217, 149-153.
177. Marangos, P. J.; Paul, S. M.; Parma, A. M.; Goodwin, F. K.; Syapin, P.; Skolnick, P. Purinergic inhibition of diazepam binding to rat brain (in vitro). Life Sci. 1979, 24, 851-857.
178. Sattin, A.; Rall, T. W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 31, 51-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 1970, 6, 13-23.
179. Cardinali, D. P. Methylxanthines: Possible mechanisms of action in brain. Trends Pharmacol. Sci. 1980, 1, 405-407.
180. Butcher, R. W.; Sutherland, E. W. Adenosine 31, 51-Phosphate in Biological Materials: I. Purification and properties of cyclic 31, 51-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 31, 51-phosphate in human urine. J. Biol. Chem. 1962, 237, 1244-1250.
181. Nicholson, C. D.; Jackman, S. A.; Wilke, R. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br. J. Pharmacol. 1989, 97, 889-897.
182. Geraets, L.; Moonen, H. J. J.; Wouters, E. F. M.; Bast, A.; Hageman, G. J. Caffeine metabolites are inhibitors of the nuclear enzyme poly (ADP-ribose) polymerase-1 at physiological concentrations. Biochem. Pharmacol. 2006, 72, 902-910.
183. Rao, F. V.; Andersen, O. A.; Vora, K. A.; De Martino, J. A.; van Aalten, D. M. F. Methylxanthine drugs are chitinase inhibitors: Investigation of inhibition and binding modes. Chem. Biol. 2005, 12, 973-980.
184. Ito, K.; Lim, S.; Caramori, G.; Cosio, B.; Chung, K. F.; Adcock, I. M.; Barnes, P. J. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA 2002, 99, 8921-8926.
185. Cosio, B. G.; Tsaprouni, L.; Ito, K.; Jazrawi, E.; Adcock, I. M.; Barnes, P. J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004, 200, 689-695.
186. Pohanka, M.; Dobes, P. Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. Int. J. Mol. Sci. 2013, 14, 9873-9882.
187. Miroslav, P. The effects of caffeine on the cholinergic system. Mini Rev. Med. Chem. 2014, 14, 543-549.
188. Petzer, A.; Pienaar, A.; Petzer, J. P. The interactions of caffeine with monoamine oxidase. Life Sci. 2013, 93, 283-287.
189. Gattuso, G.; Manfredi, G.; Sammartano, S. Quantitative study on the non-covalent interactions between ATP and caffeine, theophylline and theobromine in aqueous solution. Fluid Phase Equilibria 2011, 308, 47-54.
190. Johnson, I. M.; Prakash, H.; Prathiba, J.; Raghunathan, R.; Malathi, R. Spectral analysis of naturally occurring methylxanthines (theophylline, theobromine and caffeine) binding with DNA. PLoS ONE 2012, 7, e50019.
191. Johnson, I. M.; Kumar, S. G. B.; Malathi, R. RNA binding efficacy of theophylline, theobromine and caffeine. J. Biomol. Struct. Dyn. 2003, 20, 687-692.
192. Martínez-Pinilla, E.; Oñatibia-Astibia, A.; Franco, R. The relevance of theobromine for the beneficial effects of cocoa consumption. Front. Pharmacol. 2015, 6, 1-5.
193. Arnaud, M. J. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. In Methylxanthines; Springer: Berlin/Heidelberg, Germany, 2011; pp. 33-91.
194. Lelo, A.; Birkett, D. J.; Robson, R. A.; Miners, J. O. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br. J. Cl. Pharmacol. 1986, 22, 177-182.
195. Blanchard, J.; Sawers, S. J. A. The absolute bioavailability of caffeine in man. Eur. J. Clin. Pharmacol. 1983, 24, 93-98.
196. Zandvliet, A. S.; Huitema, A. D. R.; de Jonge, M. E.; den Hoed, R.; Sparidans, R. W.; Hendriks, V. M.; van Den Brink, W.; van Ree, J. M.; Beijnen, J. H. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. Basic Clin. Pharmacol. Toxicol. 2005, 96, 71-79.
197. Teekachunhatean, S.; Tosri, N.; Rojanasthien, N.; Srichairatanakool, S.; Sangdee, C. Pharmacokinetics of caffeine following a single administration of coffee enema versus oral coffee consumption in healthy male subjects. ISRN Pharmacol. 2013, 2013, 7.
198. Perera, V.; Gross, A. S.; McLachlan, A. J. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed. Chromatogr. 2010, 24, 1136-1144.
199. Becker, A. B.; Simons, K. J.; Gillespie, C. A.; Simons, F. E. R. The bronchodilator effects and pharmacokinetics of caffeine in asthma. N. Engl. J. Med. 1984, 310, 743-746.
200. French, I. W.; Mildon, C. A. The pharmacokinetics of theophylline. Curr. Med. Res. Opin. 1979, 6 (Suppl. S6), 3-13.
201. Resman, B. H.; Blumenthal, H. P.; Jusko, W. J. Breast milk distribution of theobromine from chocolate. J. Pediatr. 1977, 91, 477-480.
202. Mumford, K. G.; Benowitz, L. N.; Evans, M. S.; Kaminski, J. B.; Preston, L. K.; Sannerud, A. C.; Silverman, K.; Griffiths, R. R. Absorption rate of methylxanthines following capsules, cola and chocolate. Eur. J. Clin. Pharmacol. 1996, 51, 319-325.
203. Laska, E. M.; Sunshine, A.; Mueller, F.; Elvers, W. B.; Siegel, C.; Rubin, A. Caffeine as an analgesic adjuvant. JAMA 1984, 251, 1711-1718.
204. Derry, C. J.; Derry, S.; Moore, R. A. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst. Rev. 2014, 12, 1-62.
205. Lee, I.-A.; Kamba, A.; Low, D.; Mizoguchi, E. Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. World J. Gastroenterol. 2014, 20, 1127-1138.
206. Beaumont, M.; Batéjat, D.; Coste, O.; Doireau, P.; Chauffard, F.; Enslen, M.; Lagarde, D.; Pierard, C. Recovery after prolonged sleep deprivation: Residual effects of slow-release caffeine on recovery sleep, sleepiness and cognitive functions. Neuropsychobiology 2005, 51, 16-27.
207. Lozano, R. P.; García, Y. A.; Tafalla, D. B.; Albaladejo, M. F. Cafeína: Un nutriente, un fármaco, o una droga de abuso. Adicciones 2007, 19, 225-238.
208. Smit, H. J.; Gaffan, E. A.; Rogers, P. J. Methylxanthines are the psycho-pharmacologically active constituents of chocolate. Psychopharmacology 2004, 176, 412-419.
209. Takahashi, R. N.; Pamplona, F. A.; Prediger, R. D. Adenosine receptor antagonists for cognitive dysfunction: A review of animal studies. Front. Biosci. 2008, 13, 2614-2632.
210. Angelucci, M. E. M.; Cesário, C.; Hiroi, R. H.; Rosalen, P. L.; Cunha, C. D. Effects of caffeine on learning and memory in rats tested in the Morris water maze. Braz. J. Med. Biol. Res. 2002, 35, 1201-1208.
211. Lieberman, H. R. The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood and energy. Nutr. Rev. 2001, 59, 91-102.
212. Haskell, C. F.; Kennedy, D. O.; Wesnes, K. A.; Scholey, A. B. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology 2005, 179, 813-825.
213. Riedel, W.; Hogervorst, E.; Leboux, R.; Verhey, F.; van Praag, H.; Jolles, J. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 1995, 122, 158-168.
214. Maia, L.; de Mendonça, A. Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 2002, 9, 377-382.
215. Arendash, G. W.; Cao, C. Caffeine and coffee as therapeutics against Alzheimer's disease. J. Alzheimers Dis. 2010, 20, S117-S126.
216. Eskelinen, M. H.; Ngandu, T.; Tuomilehto, J.; Soininen, H.; Kivipelto, M. Midlife coffee and tea drinking and the risk of latelife dementia: A population-based CAIDE study. J. Alzheimers Dis. 2009, 16, 85-91.
217. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21, RC143.
218. Costa, J.; Lunet, N.; Santos, C.; Santos, J.; Vaz-Carneiro, A. Caffeine exposure and the risk of Parkinson's disease: A systematic review and meta-analysis of observational studies. J. Alzheimers Dis. 2010, 20, S221-S238.
219. Postuma, R. B.; Lang, A. E.; Munhoz, R. P.; Charland, K.; Pelletier, A.; Moscovich, M.; Filla, L.; Zanatta, D.; Rios Romenets, S.; Altman, R.; et al. Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology 2012, 79, 651-658.
220. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 2011, 19, 1283-1293.
221. Chen, X.; Gawryluk, J. W.; Wagener, J. F.; Ghribi, O.; Geiger, J. D. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflammation 2008, 5, 12.
222. Chen, X.; Lan, X.; Roche, I.; Liu, R.; Geiger, J. D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J. Neurochem. 2008, 107, 1147-1157.
223. Arendash, G. W.; Schleif, W.; Rezai-Zadeh, K.; Jackson, E. K.; Zacharia, L. C.; Cracchiolo, J. R.; Shippy, D.; Tan, J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience 2006, 142, 941-952.
224. Cao, C.; Cirrito, J. R.; Lin, X.; Wang, L.; Verges, D. K.; Dickson, A.; Mamcarz, M.; Zhang, C.; Mori, T.; Arendash, G. W.; et al. Caffeine suppresses β-amyloid levels in plasma and brain of Alzheimer's transgenic mice. J. Alzheime's Dis. JAD 2009, 17, 681-697.
225. Chu, Y.-F.; Chang, W.-H.; Black, R. M.; Liu, J.-R.; Sompol, P.; Chen, Y.; Wei, H.; Zhao, Q.; Cheng, I. H. Crude caffeine reduces memory impairment and amyloid β1-42 levels in an Alzheimer's mouse model. Food Chem. 2012, 135, 2095-2102.
226. Arendash, G. W.; Mori, T.; Cao, C.; Mamcarz, M.; Runfeldt, M.; Dickson, A.; Rezai-Zadeh, K.; Tane, J.; Citron, B. A.; et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J. Alzheimers Dis. 2009, 17, 661-680.
227. Lindsay, J.; Laurin, D.; Verreault, R.; Hébert, R.; Helliwell, B.; Hill, G. B.; McDowell, I. Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 2002, 156, 445-453.
228. Ritchie, K.; Carrière, I.; de Mendonça, A.; Portet, F.; Dartigues, J. F.; Rouaud, O.; Barberger-Gateau, P.; Ancelin, M. L. The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 2007, 69, 536-545.
229. Johnson-Kozlow, M.; Kritz-Silverstein, D.; Barrett-Connor, E.; Morton, D. Coffee consumption and cognitive function among older adults. Am. J. Epidemiol. 2002, 156, 842-850.
230. Van Gelder, B. M.; Buijsse, B.; Tijhuis, M.; Kalmijn, S.; Giampaoli, S.; Nissinen, A.; Kromhout, D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur. J. Clin. Nutr. 2006, 61, 226-232.
231. Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; et al. Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience 2008, 151, 1198-1207.
232. Sonsalla, P. K.; Wong, L.-Y.; Harris, S. L.; Richardson, J. R.; Khobahy, I.; Li, W.; Gadad, B. S.; German, D. C. Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. Exp. Neurol. 2012, 234, 482-487.
233. Benedetti, M. D.; Bower, J. H.; Maraganore, D. M.; McDonnell, S. K.; Peterson, B. J.; Ahlskog, J. E.; Schaid, D. J.; Rocca, W. A. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: A case-control study. Neurology 2000, 55, 1350-1358.
234. Ross, G.; Abbott, R. D.; Petrovitch, H.; Morens, D. M.; Grandinetti, A.; Tung, K. H.; Tanner, C. M.; Masaki, K. H.; Blanchette, P. L.; Curb, J. D.; et al. Association of coffee and caffeine intake with the risk of parkinson disease. JAMA 2000, 283, 2674-2679.
235. Saaksjarvi, K.; Knekt, P.; Rissanen, H.; Laaksonen, M. A.; Reunanen, A.; Mannisto, S. Prospective study of coffee consumption and risk of Parkinson's disease. Eur. J. Clin. Nutr. 2007, 62, 908-915.
236. Ascherio, A.; Zhang, S. M.; Hernán, M. A.; Kawachi, I.; Colditz, G. A.; Speizer, F. E.; Willett, W. C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50, 56-63.
237. Palacios, N.; Gao, X.; McCullough, M. L.; Schwarzschild, M. A.; Shah, R.; Gapstur, S.; Ascherio, A. Caffeine and risk of Parkinson disease in a large cohort of men and women. Mov. Disord. 2012, 27, 1276-1282.
238. Qi, H.; Li, S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatr. Gerontol. Int. 2014, 14, 430-439.
239. 2A receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Ann. Neurol. 2013, 73, 655-666.
240. Simonin, C.; Duru, C.; Salleron, J.; Hincker, P.; Charles, P.; Delval, A.; Youssov, K.; Burnouf, S.; Azulay, J.-P.; Verny, C.; et al. Association between caffeine intake and age at onset in Huntington's disease. Neurobiol. Dis. 2013, 58, 179-182.
241. Henderson-Smart, D. J.; De Paoli, A. G. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst. Rev. 2010, 8.
242. Comer, A. M.; Perry, C. M.; Figgitt, D. P. Caffeine citrate: A review of its use in apnoea of prematurity. Paediatric Drugs 2001, 3, 61-79.
243. Bhatia, J. Current options in the management of apnea of prematurity. Clin. Pediatr. 2000, 39, 327-336.
244. Aranda, J. V.; Beharry, K.; Valencia, G. B.; Natarajan, G.; Davis, J. Caffeine impact on neonatal morbidities. J. Matern. Fetal Neonatal Med. 2010, 23 (Suppl. S3), 20-23.
245. Schoen, K.; Yu, T.; Stockmann, C.; Spigarelli, M. G.; Sherwin, C. M. T. Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. Pediatr. Drugs 2014, 16, 169-177.
246. Lagercrantz, H.; Yamamoto, Y.; Fredholm, B. B.; Prabhakar, N. R.; von Euler, C. Adenosine analogues depress ventilation in rabbit neonates. Theophylline stimulation of respiration via adenosine receptors? Pediatr. Res. 1984, 18, 387-390.
247. Kawai, A.; Okada, Y.; Mückenhoff, K.; Scheid, P. Theophylline and hypoxic ventilatory response in the rat isolated brainstem-spinal cord. Respir. Physiol. 1995, 100, 25-32.
248. Wennergren, G.; Wennergren, M. Neonatal breathing control mediated via the central chemoreceptors. Acta Physiol. Scand. 1983, 119, 139-146.
249. Herlenius, E.; Lagercrantz, H. Adenosinergic modulation of respiratory neurones in the neonatal rat brainstem in vitro. J. Physiol. 1999, 518, 159-172.
250. Eldridge, F. L.; Millhorn, D. E.; Kiley, J. P. Antagonism by theophylline of respiratory inhibition induced by adenosine. J. Appl. Physiol. 1985, 59, 1428-1433.
251. Hedner, T.; Hedner, J.; Bergman, B.; Mueller, R. A.; Jonason, J. Characterization of adenosine-induced respiratory depression in the preterm rabbit. Biol. Neonate 1985, 47, 323-332.
252. Mosca, E. V.; Ciechanski, P.; Roy, A.; Scheibli, E. C.; Ballanyi, K.; Wilson, R. J. A. Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: Mechanism and location of action. Respir. Physiol. Neurobiol. 2014, 200, 80-89.
253. Barnes, P. J. Theophylline in chronic obstructive pulmonary disease: New horizons. Proc. Am. Thorac. Soc. 2005, 2, 334-339.
254. Fozard, J. R.; McCarthy, C. Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs 2002, 3, 69-77.
255. Russo, C.; Arcidiacono, G.; Polosa, R. Adenosine receptors: Promising targets for the development of novel therapeutics and diagnostics for asthma. Fundam. Clin. Pharmacol. 2006, 20, 9-19.
256. Barnes, P. J. Theophylline for COPD. Thorax 2006, 61, 742-744.
257. Usmani, O. S.; Belvisi, M. G.; Patel, H. J.; Crispino, N.; Birrell, M. A.; Korbonits, M.; Korbonits, D.; Barnes, P. J. Theobromine inhibits sensory nerve activation and cough. FASEB J. 2004.
258. Smit, H. J. Theobromine and the pharmacology of cocoa. In Methylxanthines; Springer: Berlin, Germany; Heidelberg, Germany, 2011; pp. 201-234.
259. Riksen, N. P.; Smits, P.; Rongen, G. A. The cardiovascular effects of methylxanthines. In Methylxanthines; Springer: Berlin, Germany; Heidelberg, Germany, 2011; pp. 413-437.
260. Cameron, O. G.; Modell, J. G.; Hariharan, M. Caffeine and human cerebral blood flow: A positron emission tomography study. Life Sci. 1990, 47, 1141-1146.
261. Okuno, T.; Sugiyama, T.; Tominaga, M.; Kojima, S.; Ikeda, T. Effects of caffeine on microcirculation of the human ocular fundus. Jpn. J. Ophthalmol. 2002, 46, 170-176.
262. Batterman, R. G.; Grossman, A. J.; Dubinsky, J.; Mouratoff, G. Reevaluation of the usefullness of theobromine calcium gluconate for the management of congestive heart failure and anginal syndrome. Int. Rec. Med. Gen. Pract. Clin. 1959, 172, 318-323.
263. Larsson, S. C.; Orsini, N. Coffee consumption and risk of stroke: A dose-response meta-analysis of prospective studies. Am. J. Epidemiol. 2011, 174, 993-1001.
264. Ding, M.; Bhupathiraju, S. N.; Satija, A.; van Dam, R. M.; Hu, F. B. Long-term coffee consumption and risk of cardiovascular disease: A systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014, 129, 643-659.
265. Bohn, S. K.; Ward, N. C.; Hodgson, J. M.; Croft, K. D. Effects of tea and coffee on cardiovascular disease risk. Food Funct. 2012, 3, 575-591.
266. Khan, N.; Monagas, M.; Andres-Lacueva, C.; Casas, R.; Urpí-Sardà, M.; Lamuela-Raventós, R. M.; Estruch, R. Regular consumption of cocoa powder with milk increases HDL cholesterol and reduces oxidized LDL levels in subjects at high-risk of cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 1046-1053.
267. Kris-Etherton, P. M.; Derr, J. A.; Mustad, V. A.; Seligson, F. H.; Pearson, T. A. Effects of a milk chocolate bar per day substituted for a high-carbohydrate snack in young men on an NCEP/AHA Step 1 Diet. Am. J. Clin. Nutr. 1994, 60, 1037S-1042S.
268. Mursu, J.; Voutilainen, S.; Nurmi, T.; Rissanen, T. H.; Virtanen, J. K.; Kaikkonen, J.; Nyyssönen, K.; Salonen, J. T. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic. Biol. Med. 2004, 37, 1351-1359.
269. Baba, S.; Osakabe, N.; Kato, Y.; Natsume, M.; Yasuda, A.; Kido, T.; Fukuda, K.; Muto, Y.; Kondo, K. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans. Am. J. Clin. Nutr. 2007, 85, 709-717.
270. Mellor, D. D.; Sathyapalan, T.; Kilpatrick, E. S.; Beckett, S.; Atkin, S. L. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. Diabet. Med. 2010, 27, 1318-1321.
271. Neufingerl, N.; Zebregs, Y. E.; Schuring, E. A.; Trautwein, E. A. Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: A randomized controlled trial. Am. J. Clin. Nutr. 2013, 97, 1201-1209.
272. Inoue, H.; Kobayashi-Hattori, K.; Horiuchi, Y.; Oishi, Y.; Arai, S.; Takita, T. Regulation of the body fat percentage in developmental-stage rats by methylxanthine derivatives in a high-fat diet. Biosci. Biotechnol. Biochem. 2006, 70, 1134-1139.
273. Heppel, L. A.; Porterfield, V. T.; Peake, E. G. The lipotropic activity of caffeine, theobromine and theophylline. Arch. Biochem. Biophys. 1947, 15, 439-443.
274. Bray, G. A.; Mothon, S.; Cohen, A. S. Mobilization of fatty acids in genetically obese rats. J. Lipid Res. 1970, 11, 517-521.
275. Kuo, J. F.; de Renzo, E. C. A comparison of the effects of lipolytic and antilipolytic agents on adenosine 31, 51-monophosphate levels in adipose cells as determined by prior labeling with adenine-8-14C. J. Biol. Chem. 1969, 244, 2252-2260.
276. Acheson, K. J.; Gremaud, G.; Meirim, I.; Montigon, F.; Krebs, Y.; Fay, L. B.; Gay, L.-J.; Schneiter, P.; Schindler, C.; Tappy, L. Metabolic effects of caffeine in humans: Lipid oxidation or futile cycling? Am. J. Clin. Nutr. 2004, 79, 40-46.
277. Kim, T.-W.; Shin, Y.-O.; Lee, J.-B.; Min, Y.-K.; Yang, H.-M. Effect of caffeine on the metabolic responses of lipolysis and activated sweat gland density in human during physical activity. Food Sci. Biotechnol. 2010, 19, 1077-1081.
278. Lopez-Garcia, E.; van Dam, R. M.; Rajpathak, S.; Willett, W. C.; Manson, J. E.; Hu, F. B. Changes in caffeine intake and long-term weight change in men and women. Am. J. Clin. Nutr. 2006, 83, 674-680.
279. Westerterp-Plantenga, M. S.; Lejeune, M. P. G. M.; Kovacs, E. M. R. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes. Res. 2005, 13, 1195-1204.
280. Davis, J. O.; Shock, N. W. The effect of theophylline ethylene diamine on renal function in control subjects and in patients with congestive heart failure. J. Clin. Investig. 1949, 28 Pt. 2, 1459-1468.
281. Osswald, H.; Schnermann, J. Methylxanthines and the kidney. Handb. Exp. Pharmacol. 2011, 200, 391-412.
282. 1 receptor antagonist. J. Am. Soc. Nephrol. 1999, 10, 714-720.
283. 1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. J. Pharmacol. Exp. Ther. 2005, 313, 403-409.
284. Fredholm, B. B.; Hedqvist, P.; Vernet, L. Effect of theophylline and other drugs on rabbit renal cyclic nucleotide phosphodiesterase, 51-nucleotidase and adenosine deaminase. Biochem. Pharmacol. 1978, 27, 2845-2850.
285. Coulson, R.; Scheinman, S. J. Xanthine effects on renal proximal tubular function and cyclic AMP metabolism. J. Pharmacol. Exp. Ther. 1989, 248, 589-595.
286. Bhupathiraju, S. N.; Pan, A.; Malik, V. S.; Manson, J. E.; Willett, W. C.; van Dam, R. M.; Hu, F. B. Caffeinated and caffeine-free beverages and risk of type 2 diabetes. Am. J. Clin. Nutr. 2013, 97, 155-166.
287. Biessels, G. J. Caffeine, diabetes, cognition, and dementia. J. Alzheimers Dis. 2010, 20 (Suppl. S1), S143-S150.
288. Bidel, S.; Hu, G.; Qiao, Q.; Jousilahti, P.; Antikainen, R.; Tuomilehto, J. Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes. Diabetologia 2006, 49, 2618-2626.
289. Muley, A.; Muley, P.; Shah, M. Coffee to reduce risk of type 2 diabetes? A systematic review. Curr. Diabetes Rev. 2012, 8, 162-168.
290. Van Dam, R. M.; Feskens, E. J. M. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2002, 360, 1477-1478.
291. Van Dam, R. M.; Hu, F. B. Coffee consumption and risk of type 2 diabetes: A systematic review. JAMA 2005, 294, 97-104.
292. Paynter, N. P.; Yeh, H.-C.; Voutilainen, S.; Schmidt, M. I.; Heiss, G.; Folsom, A. R.; Brancati, F. L.; Kao, W. H. L. Coffee and sweetened beverage consumption and the risk of type 2 diabetes mellitus: The atherosclerosis risk in communities study. Am. J. Epidemiol. 2006, 164, 1075-1084.
293. Sartorelli, D. S.; Fagherazzi, G.; Balkau, B.; Touillaud, M. S.; Boutron-Ruault, M.-C.; de Lauzon-Guillain, B.; Clavel-Chapelon, F. Differential effects of coffee on the risk of type 2 diabetes according to meal consumption in a French cohort of women: The E3N/EPIC cohort study. Am. J. Clin. Nutr. 2010, 91, 1002-1012.
294. Ding, M.; Bhupathiraju, S. N.; Chen, M.; van Dam, R. M.; Hu, F. B. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: A systematic review and a dose-response meta-analysis. Diabetes Care 2014, 37, 569-586.
295. Dieren, S.; Uiterwaal, C. S. P. M.; Schouw, Y. T.; van der A. D. L.; Boer, J. M. A.; Spijkerman, A.; Grobbee, D. E.; Beulens, J. W. J. Coffee and tea consumption and risk of type 2 diabetes. Diabetologia 2009, 52, 2561-2569.
296. Yang, W.-S.; Wang, W.-Y.; Fan, W.-Y.; Deng, Q.; Wang, X. Tea consumption and risk of type 2 diabetes: A dose-response meta-analysis of cohort studies. Br. J. Nutr. 2014, 111, 1329-1339.
297. Pereira, M. A.; Parker, E. D.; Folsom, A. R. Coffee consumption and risk of type 2 diabetes mellitus: An 11-year prospective study of 28, 812 postmenopausal women. Arch. Intern. Med. 2006, 166, 1311-1316.
298. Van Dam, R. M.; Willett, W. C.; Manson, J. E.; Hu, F. B. Coffee, caffeine, and risk of type 2 diabetes: A prospective cohort study in younger and middle-aged U. S. women. Diabetes Care 2006, 29, 398-403.
299. Sarriá, B.; Martínez-López, S.; Sierra-Cinos, J. L.; Garcia-Diz, L.; Goya, L.; Mateos, R.; Bravo, L. Effects of bioactive constituents in functional cocoa products on cardiovascular health in humans. Food Chem. 2015, 174, 214-218.
300. Seino, S.; Takahashi, H.; Fujimoto, W.; Shibasaki, T. Roles of cAMP signalling in insulin granule exocytosis. Diabetes Obes. Metab. 2009, 11, 180-188.
301. Vilela, V. R.; de Oliveira, A. L.; Comar, J. F.; Peralta, R. M.; Bracht, A. Tadalafil inhibits the cAMP stimulated glucose output in the rat liver. Chem. Biol. Interact. 2014, 220, 1-11.
302. Huang, M.-T.; Xie, J.-G.; Wang, Z. Y.; Ho, C.-T.; Lou, Y.-R.; Wang, C.-X.; Hard, G. C.; Conney, A. H. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: Demonstration of caffeine as a biologically important constitutent of tea. Cancer Res. 1997, 57, 2623-2629.
303. Lu, Y.-P.; Lou, Y.-R.; Xie, J.-G.; Peng, Q.-Y.; Liao, J.; Yang, C. S.; Huang, M.-T.; Conney, A. H. Topical applications of caffeine or (β)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc. Natl. Acad. Sci. USA 2002, 99, 12455-12460.
304. Lu, Y.-P.; Lou, Y.-R.; Xie, J.-G.; Peng, Q.-Y.; Zhou, S.; Lin, Y.; Shih, W. J.; Conney, A. H. Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis 2006, 28, 199-206.
305. Ryzhov, S.; McCaleb, J. L.; Goldstein, A. E.; Biaggioni, I.; Feoktistov, I. Role of Adenosine Receptors in the Regulation of Angiogenic Factors and Neovascularization in Hypoxia. J. Pharmacol. Exp. Ther. 2007, 320, 565-572.
306. Chung, F.-L.; Wang, M.; Rivenson, A.; Iatropoulos, M. J.; Reinhardt, J. C.; Pittman, B.; Ho, C.-T.; Amin, S. G. Inhibition of lung carcinogenesis by black tea in fischer rats treated with a tobacco-specific carcinogen: Caffeine as an important constituent. Cancer Res. 1998, 58, 4096-4101.
307. Lu, G.; Liao, J.; Yang, G.; Reuhl, K. R.; Hao, X.; Yang, C. S. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006, 66, 11494-11501.
308. Yang, H.; Rouse, J.; Lukes, L.; Lancaster, M.; Veenstra, T.; Zhou, M.; Shi, Y.; Park, Y.-G.; Hunter, K. Caffeine suppresses metastasis in a transgenic mouse model: A prototype molecule for prophylaxis of metastasis. Clin. Exp. Metastasis 2005, 21, 719-735.
309. Gude, R. P.; Menon, L. G.; Rao, S. G. Effect of Caffeine, a xanthine derivative, in the inhibition of experimental lung metastasis induced by B16F10 melanoma cells. J. Exp. Clin. Cancer Res. 2001, 20, 287-292.
310. Merighi, S.; Benini, A.; Mirandola, P.; Gessi, S.; Varani, K.; Simioni, C.; Leung, E.; Maclennan, S.; Baraldi, P. G.; Borea, P. A. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol. Pharmacol. 2007, 72, 395-406.
311. Shukla, V.; Gude, R. P. Potentiation of lipid peroxidation in B16F10 and B16F1 melanoma cells by caffeine, a methylxanthine derivative: Relationship to intracellular glutathione. Chemotherapy 2003, 49, 71-75.
312. Hashimoto, T.; He, Z.; Ma, W.-Y.; Schmid, P. C.; Bode, A. M.; Yang, C. S.; Dong, Z. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res. 2004, 64, 3344-3349.
313. Makower, D.; Malik, U.; Novik, Y.; Wiernik, P. H. Therapeutic efficacy of theophylline in chronic lymphocytic leukemia. Med. Oncol. 1999, 16, 69-71.
314. Basu, S.; Mitra Basu, R. Theophylline as a therapy for chronic lymphocytic leukemia: A case report and review of literature. Haematologia 2000, 30, 225-227.
315. Hirsh, L.; Dantes, A.; Suh, B.-S.; Yoshida, Y.; Hosokawa, K.; Tajima, K.; Kotsuji, F.; Merimsky, O.; Amsterdam, A. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem. Pharmacol. 2004, 68, 981-988.
316. Barcz, E.; Sommer, E.; Sokolnicka, I.; Gawrychowski, K.; Roszkowska-Purska, K.; Janik, P.; Skopinska-Rózewska, E. The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells. Oncol. Rep. 1998, 5, 517-537.
317. Barcz, E.; Sommer, E.; Janik, P.; Marianowski, L.; Skopinska-Rózewska, E. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol. Rep. 2000, 7, 1285-1291.
318. Gil, M.; Skopińska-Rózewska, E.; Radomska, D.; Demkow, U.; Skurzak, H.; Rochowska, M.; Beuth, J.; Roszkowski, K. Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice. Folia Biol. 1993, 39, 63-68.
319. Takahashi, M.; Yanoma, S.; Yamamoto, Y.; Rino, Y.; Amano, T.; Imada, T. Combined effect of CDDP and caffeine against human gastric cell line in vivo. Anticancer Res. 1998, 18, 4399-4401.
320. Fingert, H. J.; Pu, A. T.; Chen, Z. Y.; Perdee, A. B. In vivo and in vitro enhanced antitumour effect by pentoxifylline in human cancer cells treated with Thiothepa. Cancer Res. 1988, 48, 4375-4381.
321. Fingert, H. J.; Chang, J. D.; Pardee, A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res. 1986, 46, 2463-2467.
322. Kawahara, M.; Takashi, Y.; Takazawa, K.; Tsuchiya, H.; Tomita, K.; Yokogawa, K.; Miyamoto, K.-I. Caffeine Dose-dependently Potentiates the Antitumor Effect of Cisplatin on Osteosarcomas. Anticancer Res. 2008, 28, 1681-1685.
323. Miwa, S.; Kitamura, S.; Shirai, T.; Hayashi, K.; Nishida, H.; Takeuchi, A.; Nojima, T.; Tsuchiya, H. Desmoplastic small round cell tumour successfully treated with caffeine-assisted chemotherapy: A case report and review of the literature. Anticancer Res. 2010, 30, 3769-3774.
324. Hayashi, M.; Tsuchiya, H.; Yamamoto, N.; Karita, M.; Shirai, T.; Nishida, H.; Takeuchi, A.; Tomita, K. Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res. 2005, 25, 2399-2405.
325. Kakuyama, A.; Sadzuka, Y. Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity. Curr. Drug Metab. 2001, 2, 379-395.
326. Tsuchiya, H.; Yasutake, H.; Yokogawa, A.; Baba, H.; Ueda, Y.; Tomita, K. Effect of chemotherapy combined with caffeine for osteosarcoma. J. Cancer Res. Clin. Oncol. 1992, 118, 567-569.
327. Busse, P. M.; Bose, S. K.; Jones, R. W.; Tolmach, L. J. The action of caffeine on X-Irradiated HeLa cells: III. Enhancement of X-ray-induced killing during G2 arrest. Radiat. Res. 1978, 76, 292-307.
328. Malki, A. M.; Gentry, J.; Evans, S. C. Differential effect of selected methylxanthine derivatives on radiosensitization of lung carcinoma cells. Exp. Oncol. 2006, 28, 16-24.
329. Youn, H.; Hee Kook, Y.; Oh, E.-T.; Jeong, S.-Y.; Kim, C.; Kyung Choi, E.; Uk Lim, B.; Park, H. J. 1-Methylxanthine enhances the radiosensitivity of tumor cells. Int. J. Radiat. Biol. 2009, 85, 167-174.
330. Bode, A. M.; Dong, Z. The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett. 2007, 247, 26-39.
331. Sabisz, M.; Skladanowski, A. Modulation of cellular response to anticancer treatment by caffeine: Inhibition of cell cycle checkpoints, DNA repair and more. Curr. Pharm. Biotechnol. 2008, 9, 325-336.
332. Zhou, B.-B. S.; Chaturvedi, P.; Spring, K.; Scott, S. P.; Johanson, R. A.; Mishra, R.; Mattern, M. R.; Winkler, J. D.; Khanna, K. K. Caffeine abolishes the mammalian G2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J. Biol. Chem. 2000, 275, 10342-10348.
333. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3, 513-519.
334. Jha, M. N.; Bamburg, J. R.; Bernstein, B. W.; Bedford, J. S. Caffeine eliminates-ray-induced G2-phase delay in human tumor cells but not in normal cells. Radiat. Res. 2002, 157, 26-31.
335. Dias, T. R.; Alves, M. G.; Bernardino, R. L.; Martins, A. D.; Moreira, A. C.; Silva, J.; Barros, A.; Sousa, M.; Silva, B. M.; Oliveira, P. F. Dose-dependent effects of caffeine in human Sertoli cells metabolism and oxidative profile: Relevance for male fertility. Toxicology 2015, 328, 12-20.
336. 2+ transport in abalone spermatozoa. J. Biol. Chem. 1984, 259, 5514-20.
337. Tash, J. S.; Means, A. R. Regulation of protein phosphorylation and motility of sperm by cyclic adenosine monophosphate and calcium. Biol. Reprod. 1982, 26, 745-763.
338. Brokaw, C. J. Regulation of sperm flagellar motility by calcium and cAMP-dependent phosphorylation. J. Cell. Biochem. 1987, 35, 175-184.
339. Dias, T. R.; Alves, M. G.; Tomas, G. D.; Socorro, S.; Silva, B. M.; Oliveira, P. F. White tea as a promising antioxidant medium additive for sperm storage at room temperature: A comparative study with green tea. J. Agric. Food Chem. 2014, 62, 608-617.
340. 2. J. Reprod. Dev. 2009, 55, 645-649.
341. Klemmer, I.; Yagi, S.; Gressner, O. A. Oral application of 1, 7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis. Hepatol. Res. 2011, 41, 1094-1109.
342. Modi, A. A.; Feld, J. J.; Park, Y.; Kleiner, D. E.; Everhart, J. E.; Liang, T. J.; Hoofnagle, J. H. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010, 51, 201-209.
343. Grases, F.; Rodriguez, A.; Costa-Bauza, A. Theobromine inhibits uric acid crystallization. A potential application in the treatment of uric acid nephrolithiasis. PLoS ONE 2014, 9, e111184.
344. Cui, D.; Trier, K.; Zeng, J.; Wu, K.; Yu, M.; Hu, J.; Chen, X.; Ge, J. Effects of 7-methylxanthine on the sclera in form deprivation myopia in guinea pigs. Acta Ophthalmol. 2011, 89, 328-334.
345. Trier, K.; Munk Ribel-Madsen, S.; Cui, D.; Brogger Christensen, S. Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: A 36-month pilot study. J. Ocul. Biol. Dis. Inform. 2008, 1, 85-93.
346. Pollard, I.; Williamson, S.; Magre, S. Influence of caffeine administered during pregnancy on the early differentiation of fetal rat ovaries and testes. J. Dev. Physiol. 1990, 13, 59-65.
347. Chorostowska-Wynimko, J.; SkopińAska-Rózewska, E.; Sommer, E.; Rogala, E.; Skopiński, P.; Wojtasik, E. Multiple effects of theobromine on fetus development and postnatal status of the immune system. Int. J. Tissue React. 2004, 26, 53-60.
348. Skopiński, P.; Woronkowicz, M.; Skopińska-Rózewska, E.; Siwicki, A. The effects of prenatal exposure to methylxanthines. Pol. J. Vet. Sci. 2011, 14, 695-701.
349. Browne, M. L.; Bell, E. M.; Druschel, C. M.; Gensburg, L. J.; Mitchell, A. A.; Lin, A. E.; Romitti, P. A.; Correa, A. Maternal caffeine consumption and risk of cardiovascular malformations. Birth Defects Res. Part A Clin. Mol. Teratol. 2007, 79, 533-543.
350. Jahanfar, S.; Jaafar, S. H. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcome. Cochrane Database Syst. Rev. 2013, 2, CD006965.
351. Barr, H. M.; Streissguth, A. P. Caffeine use during pregnancy and child outcome: A 7-year prospective study. Neurotoxicol. Teratol. 1991, 13, 441-448.
352. Bech, B. H.; Obel, C.; Henriksen, T. B.; Olsen, J. Effect of reducing caffeine intake on birth weight and length of gestation: Randomised controlled trial. BMJ Br. Med. J. 2007, 334, 409-409.
353. Browne, M. L.; Hoyt, A. T.; Feldkamp, M. L.; Rasmussen, S. A.; Marshall, E. G.; Druschel, C. M.; Romitti, P. A. Maternal caffeine intake and risk of selected birth defects in the national birth defects prevention study. Birth Defects Res. Part A Clin. Mol. Teratol. 2011, 91, 93-101.
354. Group, C. S. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: A large prospective observational study. BMJ Br. Med. J. 2008, 337, a2332.
355. Weng, X.; Odouli, R.; Li, D.-K. Maternal caffeine consumption during pregnancy and the risk of miscarriage: A prospective cohort study. Am. J. Obstet. Gynecol. 2008, 198, 279.e1-279.e8.
356. Schmidt, R. J.; Romitti, P. A.; Burns, T. L.; Browne, M. L.; Druschel, C. M.; Olney, R. S. Maternal caffeine consumption and risk of neural tube defects. Birth Defects Res. Part A Clin. Mol. Teratol. 2009, 85, 879-889.
357. Hoyt, A. T.; Browne, M.; Richardson, S.; Romitti, P.; Druschel, C. Maternal caffeine consumption and small for gestational age births: Results from a population-based case-control study. Matern. Child Health J. 2013, 18, 1540-1551.
358. Chen, L.; Bell, E. M.; Browne, M. L.; Druschel, C. M.; Romitti, P. A.; Schmidt, R. J.; Burns, T. L.; Moslehi, R.; Olney, R. S.; National Birth Defects Prevention Study. Maternal caffeine consumption and risk of congenital limb deficiencies. Birth Defects Res. Part A Clin. Mol. Teratol. 2012, 94, 1033-1043.
359. Kuczkowski, K. M. Caffeine in pregnancy. Arch. Gynecol. Obstet. 2009, 280, 695-698.
360. Friedman, L.; Weinberger, M. A.; Farber, T. M.; Moreland, F. M.; Peters, E. L.; Gilmore, C. E.; Khan, M. A. Testicular atrophy and impaired spermatogenesis in rats fed high levels of the methylxanthines caffeine, theobromine, or theophylline. J. Environ. Pathol. Toxicol. 1979, 2, 687-706.
361. Gans, J. H. Comparative toxicities of dietary caffeine and theobromine in the rat. Food Chem. Toxicol. 1984, 22, 365-369.
362. Cappelletti, S.; Daria, P.; Sani, G.; Aromatario, M. Caffeine: Cognitive and physical performance enhancer or psychoactive drug? Curr. Neuropharmacol. 2015, 13, 71-88.
363. Hart, A. B.; de Wit, H.; Palmer, A. A. Genetic factors modulating the response to stimulant drugs in humans. Curr. Top. Behav. Neurosci. 2012, 12, 537-577.
364. Rogers, P. J.; Hohoff, C.; Heatherley, S. V.; Mullings, E. L.; Maxfield, P. J.; Evershed, R. P.; Deckert, J.; Nutt, D. J. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 2010, 35, 1973-1983.
365. 2A receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003, 28, 1694-1702.
366. Planning Committee for a Workshop on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements; Food and Nutrition Board; Board on Health Sciences Policy; Institute of Medicine. In Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary; National Academies Press (US) :Washington DC, USA, 2014.
367. Glade, M. J. Caffeine-Not just a stimulant. Nutrition 2010, 26, 932-938.
368. Clauson, K. A.; Shields, K. M.; McQueen, C. E.; Persad, N. Safety issues associated with commercially available energy drinks. J. Am. Pharm. Assoc. 2003, 48, 55-63.
369. Banerjee, P.; Ali, Z.; Levine, B.; Fowler, D. R. Fatal caffeine intoxication: A series of eight cases from 1999 to 2009. J. Forensic Sci. 2014, 59, 865-868.
370. Stavric, B. Methylxanthines: Toxicity to humans. 2. Caffeine. Food Chem. Toxicol. 1988, 26, 645-662.
371. Tajima, Y. Coffee-induced hypokalaemia. Clin. Med. Insights Case Rep. 2010, 3, 9-13.
372. Nehlig, A. Dependence upon coffee and caffeine: An update. In Coffee, Tea, Chocolate, and the Brain; Nehlig, A., Ed.; CRC Press: Boca Raton, FL, USA, 2004; pp. 133-146.
373. Nehlig, A.; Armspach, J.-P.; Namer, I. J. SPECT assessment of brain activation induced by caffeine: No effect on areas involved in dependence. Dialogues Clin. Neurosci. 2010, 12, 255-263.
374. Baggott, M. J.; Childs, E.; Hart, A. B.; de Bruin, E.; Palmer, A. A.; Wilkinson, J. E.; de Wit, H. Psychopharmacology of theobromine in healthy volunteers. Psychopharmacology 2013, 228, 109-118.
375. Eteng, M. U.; Eyong, E. U.; Akpanyung, E. O.; Agiang, M. A.; Aremu, C. Y. Recent advances in caffeine and theobromine toxicities: A review. Plant Foods Hum. Nutr. 1997, 51, 231-243.
376. Czok, G. Concerning the question of the biological effectiveness of methylxanthines in cocoa products. Z. Ernährungswissenschaft 1974, 4, 165-170.
377. Knight, R. J.; Bowmer, C. J.; Yates, M. S. The diuretic action of 8-cyclopentyl-1, 3-dipropylxanthine, a selective A1 adenosine receptor antagonist. Br. J. Pharmacol. 1993, 109, 271-277.